Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer

Inclusion Criteria:

The subject must be ≥ 18 years old on the day of consent.
The subject is able to understand written and spoken English
The patient must have histologically or cytologically confirmed prostate adenocarcinoma.
The subject must have castration-resistant prostate cancer (CRPC)
The subject must have metastatic disease involving bone, seen on radiographic imaging (bone scan, CT scan, PET scan, or MRI).
The subject must be in a castrate state (e.g., currently receiving androgen deprivation therapy or have had an orchiectomy).
The subject must be starting any line treatment post-androgen deprivation/antiandrogen therapy, such as the following: chemotherapy (e.g., docetaxel, paclitaxel, carboplatin, cabazitaxel, or mitoxantrone); abiraterone acetate; MDV3100; ketoconazole; sipuleucel-T; Radium 223.
The subject owns or has regular access to a telephone (cellular or land line).
The subject is willing and able to self-report pain and analgesic use via an automated telephone system.
The subject is willing and able to provide informed consent.

Exclusion Criteria:

The subject has small cell or predominantly neuroendocrine differentiated prostate tumor.